Trade MGX anytime, even after market hours
Regulated by
MAS
Trusted by
400,000+ users
Metagenomi Therapeutics, Inc. (MGX) is trading at US$1.17, up 0.86% today as of Sep 4, 16:00 EDT. The company has a market capitalisation of US$46.47M. Over the past 52 weeks, MGX has traded between US$1.13 and US$3.95. On Syfe you can trade MGX with $0 commission and add it to your watchlist.
| Previous close | US$1.16 |
|---|---|
| Market cap | US$46.47M |
| 52-week range | US$1.13 – US$3.95 |
| Volume | 54.79K |
| Exchange | US |
Add to Watchlist
Set Price Alert
Metagenomi Therapeutics, Inc.
Metagenomi Therapeutics, Inc. is a precision genetic medicines company, which engages in the business of developing next generation gene-editing technologies and therapies. Its business activities include developing gene editing toolbox, therapeutic focus, and processing discovery platform. The company was founded by Brian C. Thomas on September 16, 2016 and is headquartered in Emeryville, CA.
Year: 2024
--Chardan Cuts Price Target on Metagenomi to $5 From $7, Keeps Buy Rating
Jul 7, 11:55 AM · MT Newswires
Metagenomi Therapeutics, Inc. (MGX) stock is trading at US$1.17, +0.86% from the previous close of US$1.16.
The market cap for Metagenomi Therapeutics, Inc. (MGX) stock is approximately US$46.47M.
The 52-week high for Metagenomi Therapeutics, Inc. (MGX) stock is US$3.95.
The 52-week low for Metagenomi Therapeutics, Inc. (MGX) stock is US$1.13.
Metagenomi Therapeutics, Inc. (MGX) does not currently pay a dividend.
Stay on top of MGX
Price moves, news and earnings — straight to your inbox.
Est. order value
US$0.00
Snapshot
